About 200 reports

  • SAARDS SALES VOLUME AND MARKET SHARE
  • CHAPTER IV ARTHRITIS TREATMENT DRUGS PRODUCTION AND DEMAND

THEY ARE SAARDS(SLOW ACTING ANTI-RHEUMATIC DRUGS), TRADTIONAL CHINESE MEDICINE, BIOLOGICAL AGENTS AND ANTIBIOTICS.

  • Chronic Disease
  • China
  • Demand
  • Trade
  • Ltd Sichuan Xichangyangtian Pharmaceutical Co.

Rheumatoid Arthritis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026 ##.

  • Arthritis
  • Chronic Disease
  • APAC
  • World
  • Company Financials
  • SAARDS SALES VOLUME AND MARKET SHARE
  • IV. ARTHRITIS TREATMENT DRUGS PRODUCTION AND

THEY ARE SAARDS(SLOW ACTING ANTI-RHEUMATIC DRUGS), TRADTIONAL CHINESE MEDICINE, BIOLOGICAL AGENTS AND ANTIBIOTICS.

  • Chronic Disease
  • Stroke
  • China
  • Demand
  • Yunnan Baiyao Group Co., Ltd.
  • Cardiovascular Diseases

one of the world' s leading providers of company operational data and strategic analysis, providing detailed information on tens of thousands of companies globally.

  • Biomarker
  • Cardiovascular Disease
  • Chronic Disease
  • Immunodiagnostics
  • Firalis SAS

Global Market Study on Rheumatoid Arthritis Treatment: Trends Indicate the Prevalence of New Combination Treatment and Dual Inhibitors ##.

  • Arthritis
  • Chronic Disease
  • APAC
  • World
  • Market Size

Product type include disease modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs and corticosteroids.

  • Arthritis
  • Chronic Disease
  • Pathology
  • World
  • Market Size
  • AUTOINJECTORS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2016-2023 (USD BILLION)
  • 6.2 RHEUMATOID ARTHRITIS

Glucagon-like peptide-##, commonly known as GLP-##, is a hormone produced by the proglucagon gene in the L-cells of the gut.

  • Arthritis
  • Chronic Disease
  • Stroke
  • United States
  • Amgen Inc.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

Treatment includes painkillers, NSAID and disease-modifying anti-rheumatic drugs.

  • Biosimilar
  • Chronic Disease
  • United States
  • Company Operations
  • Product Initiative
  • SEP 08, 2017: NICE ISSUES POSITIVE RECOMMENDATION FOR XELJANZ (TOFACITINIB CITRATE) AS A NEW TREATMENT OPTION FOR ADULTS WITH SEVERE RHEUMATOID ARTHRITIS

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying anti-rheumatic drug (DMARD), such as methotrexate.

  • Chronic Disease
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.
  • 5.2 MARKET DYNAMICS

Both cyclooxygenase (COX)-## selective NSAIDs (coxibs) and non-selective NSAIDs increase the risk of cardiovascular disease in patients.

  • Chronic Disease
  • North America
  • United States
  • Market Size
  • Pfizer Inc.

The guidance does not recommend abatacept in combination with methotrexate, for treating rheumatoid arthritis in adults whose disease has responded inadequately to one or more conventional non-biological disease modifying anti-rheumatic drugs (DMARDs) including methotrexate.

  • Chronic Disease
  • Musculoskeletal Disorder
  • Stroke
  • Therapy
  • Galapagos NV

Competitive Landscape ##. ## Abbvie ##. ## Biogen Idec ##. ## Bristol-Myers Squibb ##. ## Celgene ##. ## Celltrion ##. ## J& J ##. ## MedImmune ##. ## Merck ##. ## Novartis ##. ## Takeda List of Figures Figure ##-##: Representation of the Disease Progression in Rheumatoid Arthritis Figure ##-

  • Anti Rheumatic
  • Arthritis
  • Chronic Disease
  • Therapy
  • World
  • abatacept - Drug Profile

The molecules developed by Companies in Phase III, Phase II and Phase I stages are ##, ## and ## respectively.

  • Chronic Disease
  • Pharmaceutical
  • Stroke
  • Therapy
  • United States
  • and safety of the IV formulation of ORENCIA in patients with lupus nephritis.
  • ABATACEPT - DRUG PROFILE

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug (DMARD), such as methotrexate.

  • Chronic Disease
  • Neurological Disorder
  • Stroke
  • Therapy
  • Pfizer Inc.
  • Aug 03, 2017: Regeneron Reports Second Quarter 2017 Financial and Operating Results
  • Feb 09, 2017: Regeneron Reports Fourth Quarter And Full Year 2016 Financial And Operating Results

Kevzara®(sarilumab) Injection In May 2017, the FDA approved Kevzara for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response or intolerance to one or more disease modifying anti-rheumatic drugs (DMARDs).

  • Chronic Disease
  • Immunotherapy
  • Pharmaceutical
  • Stroke
  • Regeneron Pharmaceuticals, Inc.

The prominent features of this report are - ##.

  • Chronic Disease
  • Therapy
  • World
  • Product Initiative
  • UCB S.A.
  • Clinical Trial profile. 18 Trial Title

The PALACE trials evaluated the efficacy and safety of OTEZLA® twice daily (BID) versus placebo in adult subjects with active psoriatic arthritis despite prior conventional disease-modifying anti-rheumatic drugs and/ or biologics.

  • Autoimmune Disease
  • Chronic Disease
  • Targeted Therapy
  • World
  • Product Initiative

RG## specifically targets TAMs by binding to colony-stimulating factor-## receptor (CSF-##R) on the cell surface and blocking its activation by CSF-##.

  • Chronic Disease
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Plexxikon Inc.
  • and safety of the IV formulation of ORENCIA in patients with lupus nephritis.
  • ABATACEPT - DRUG PROFILE

Efficacy was maintained at ## year.

  • Chronic Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

The initial treatment option is disease-modifying antirheumatic drugs, also known as DMARDs.

  • Anti Rheumatic
  • Chronic Disease
  • Medical Biotechnology
  • Therapy
  • United States

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Chronic Disease
  • Drug Development
  • Stroke
  • Pfizer Inc.

SANTEN IS A GLOBAL SPECIALTY PHARMACEUTICAL COMPANY BASED IN JAPAN THAT FOCUSES ON THE OPHTHALMIC AND ANTI-RHEUMATIC SECTORS.

  • Chronic Disease
  • Allergan plc
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections (Vaccimil) Vaccination in Inflammatory Rheumatic Disease (VACCIMIL).

  • Chronic Disease
  • Monoclonal Antibody
  • Stroke
  • World
  • Product Initiative
  • be assessed in this study.
  • U.S. National Institutes of Health.

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug (DMARD), such as methotrexate.

  • Chronic Disease
  • Monoclonal Antibody
  • Stroke
  • United States
  • Product Initiative

Celgene Corporation P A G E | ## P A G E | ## P A G E | ## Antirheumatic drugs are used in the treatment of rheumatoid arthritis to slow down the progression of disease.

  • Chronic Disease
  • Company Financials
  • Forecast
  • GlaxoSmithKline plc
  • Pfizer Inc.

The prominent features of this report are - ##.

  • Chronic Disease
  • Clinical Trial
  • Stroke
  • Therapy
  • Otsuka Pharmaceutical Co., Ltd.

The molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Chronic Disease
  • Monoclonal Antibody
  • Stroke
  • United States
  • Novartis AG
  • FEATURED NEWS & PRESS RELEASES
  • MAR 13, 2017: BRISTOL-MYERS SQUIBB'S ORENCIA REJECTS FOR USE WITHIN NHS SCOTLAND

CST. ## RA.

  • Chronic Disease
  • Pharmaceutical
  • Stroke
  • Therapy
  • Bristol-Myers Squibb Company
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Chronic Disease
  • Neurological Disorder
  • Stroke
  • World
  • Product Initiative

The company provides drugs such as psychoneurotic, anti-cancer, cardiovascular, antihistamine, antirheumatic and benign prostatic hyperplasia drugs, among others.

  • Chronic Disease
  • Stroke
  • United States
  • Company
  • Anika Therapeutics, Inc.